Literature DB >> 6146340

The interaction between H2-receptor antagonists and beta-adrenoceptor blockers.

E Mutschler, H Spahn, W Kirch.   

Abstract

The degrees of interactions between the H2-receptor antagonists, cimetidine and ranitidine, and several beta-adrenoceptor blockers were investigated in healthy volunteers following 7 days of oral monotherapy with penbutolol, propranolol, metoprolol, pindolol and atenolol, and after co-administration with each of the H2-receptor antagonists. The kinetic parameters of unmetabolised penbutolol and penbutolol glucuronide were unaffected, whereas the levels of 4-hydroxypenbutolol and 4-hydroxypenbutolol glucuronide were significantly reduced. Furthermore, cimetidine led to a marked increase in propranolol and metoprolol plasma levels. During co-administration with cimetidine, pindolol plasma levels were only slightly raised, whereas the pharmacokinetics of atenolol were not affected. With regard to pharmacodynamics, the inhibition of exercise-induced tachycardia by each of the beta-adrenoceptor blockers was not affected by cimetidine. Ranitidine did not alter atenolol plasma levels, but did raise the peak plasma concentration of metoprolol by about 30%. It is concluded that cimetidine interactions do occur and can be predicted for substances metabolised by the cytochrome P-450 pathway.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6146340      PMCID: PMC1463269          DOI: 10.1111/j.1365-2125.1984.tb02428.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  Cimetidine and bioavailability of propranolol.

Authors:  M A Donovan; A M Heagerty; L Patel; M Castleden; J E Pohl
Journal:  Lancet       Date:  1981-01-17       Impact factor: 79.321

2.  Fluorimetric determination of atenolol in plasma and urine by direct evaluation of thin-layer chromatograms.

Authors:  M Schäfer; E Mutschler
Journal:  J Chromatogr       Date:  1979-02-01

3.  Fluorimetric determination of oxprenolol in plasma by direct evaluation of thin-layer chromatograms.

Authors:  M Schäfer; E Mutschler
Journal:  J Chromatogr       Date:  1979-10-11

4.  Delayed clearance of diazepam due to cimetidine.

Authors:  U Klotz; I Reimann
Journal:  N Engl J Med       Date:  1980-05-01       Impact factor: 91.245

5.  Interaction of metoprolol, propranolol and atenolol with concurrent administration of cimetidine.

Authors:  W Kirch; H Spahn; H Köhler; E E Ohnhaus; E Mutschler
Journal:  Klin Wochenschr       Date:  1982-11-15

6.  Does cimetidine alter the cardiac response to exercise and propranolol?

Authors:  S Warburton; L H Opie; B M Kennelly; F O Müller
Journal:  S Afr Med J       Date:  1979-06-30

7.  Cimetidine impairs elimination of chlordiazepoxide (Librium) in man.

Authors:  P V Desmond; R V Patwardhan; S Schenker; K V Speeg
Journal:  Ann Intern Med       Date:  1980-08       Impact factor: 25.391

8.  Cimetidine does not alter morphine disposition in man.

Authors:  P Mojaverian; I L Fedder; P H Vlasses; H H Rotmensch; M L Rocci; B N Swanson; R K Ferguson
Journal:  Br J Clin Pharmacol       Date:  1982-12       Impact factor: 4.335

9.  Influence of cimetidine on the pharmacokinetics of desmethyldiazepam and oxazepam.

Authors:  U Klotz; I Reimann
Journal:  Eur J Clin Pharmacol       Date:  1980-11       Impact factor: 2.953

10.  [Fluorometric determination of propranolol and its metabolite n-desisopropylpropranolol in plasma and urine by direct meausrement of thin-layer chromatographic plates (author's transl].

Authors:  M Schäfer; H E Geissler; E Mutschler
Journal:  J Chromatogr       Date:  1977-11-01
  10 in total
  10 in total

Review 1.  Clinical relevance of cimetidine drug interactions.

Authors:  A F Shinn
Journal:  Drug Saf       Date:  1992 Jul-Aug       Impact factor: 5.606

Review 2.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 3.  Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro data.

Authors:  Nina Isoherranen; Justin D Lutz; Sophie P Chung; Houda Hachad; Rene H Levy; Isabelle Ragueneau-Majlessi
Journal:  Chem Res Toxicol       Date:  2012-09-27       Impact factor: 3.739

Review 4.  Ranitidine versus cimetidine. A comparison of their potential to cause clinically important drug interactions.

Authors:  S R Smith; M J Kendall
Journal:  Clin Pharmacokinet       Date:  1988-07       Impact factor: 6.447

Review 5.  Side effects of ranitidine.

Authors:  T Vial; C Goubier; A Bergeret; F Cabrera; J C Evreux; J Descotes
Journal:  Drug Saf       Date:  1991 Mar-Apr       Impact factor: 5.606

Review 6.  Selection of drugs to treat gastro-oesophageal reflux disease: the role of drug interactions.

Authors:  D A Flockhart; Z Desta; S K Mahal
Journal:  Clin Pharmacokinet       Date:  2000-10       Impact factor: 6.447

7.  Impact of Substrate-Dependent Inhibition on Renal Organic Cation Transporters hOCT2 and hMATE1/2-K-Mediated Drug Transport and Intracellular Accumulation.

Authors:  Jia Yin; Haichuan Duan; Joanne Wang
Journal:  J Pharmacol Exp Ther       Date:  2016-10-06       Impact factor: 4.030

Review 8.  Pharmacokinetic interactions of cimetidine 1987.

Authors:  A Somogyi; M Muirhead
Journal:  Clin Pharmacokinet       Date:  1987-05       Impact factor: 6.447

9.  Penbutolol and propranolol: a comparison of their effects on antipyrine clearance in man.

Authors:  N D Bax; R W Jones; M S Lennard; G T Tucker; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1985-05       Impact factor: 4.335

10.  Repurposing Drugs in Oncology (ReDO)-Propranolol as an anti-cancer agent.

Authors:  Pan Pantziarka; Gauthier Bouche; Vidula Sukhatme; Lydie Meheus; Ilse Rooman; Vikas P Sukhatme
Journal:  Ecancermedicalscience       Date:  2016-10-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.